Incretin & metabolic research compounds
Tesofensine
Also known as NS2330
A triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor that reduced weight in a phase 2 obesity trial.
In 60 seconds
Phase 2 obesity data (2008); further development has been limited. Cardiovascular and psychiatric effects are the main questions for monoamine reuptake inhibitors; an abuse-potential study was run in recreational stimulant users.
- A phase 2 trial measured body-weight change and safety with tesofensine in obesity.
- In obese rats, tesofensine’s appetite suppression involved α1-adrenoceptor and D1 pathways.
- A randomised study assessed tesofensine’s abuse potential in recreational stimulant users.
Mechanism
By blocking reuptake of three monoamines, tesofensine suppresses appetite; animal work implicates α1-adrenoceptor and dopamine D1 pathways and silencing of GABAergic hypothalamic neurons.
Research status
Phase 2 obesity data (2008); further development has been limited. Not approved.
Key studies
A phase 2 trial measured body-weight change and safety with tesofensine in obesity.
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — Lancet, 2008 · PMID 18950853
In obese rats, tesofensine’s appetite suppression involved α1-adrenoceptor and D1 pathways.
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat — Neuropsychopharmacology, 2010 · PMID 20200509
A randomised study assessed tesofensine’s abuse potential in recreational stimulant users.
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users — Clin Pharmacol Ther, 2010 · PMID 20520602
Found tesofensine silences GABAergic neurons in the hypothalamus.
Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons — PLoS One, 2024 · PMID 38656972
Safety signals in the literature
Cardiovascular and psychiatric effects are the main questions for monoamine reuptake inhibitors; an abuse-potential study was run in recreational stimulant users.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Not stocked yet — get notified
Tell us you want Tesofensine and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Tesofensine
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Tesofensine?
A triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor that reduced weight in a phase 2 obesity trial. By blocking reuptake of three monoamines, tesofensine suppresses appetite; animal work implicates α1-adrenoceptor and dopamine D1 pathways and silencing of GABAergic hypothalamic neurons.
What is the research status of Tesofensine?
Phase 2 obesity data (2008); further development has been limited. Not approved.
What safety signals are reported for Tesofensine?
Cardiovascular and psychiatric effects are the main questions for monoamine reuptake inhibitors; an abuse-potential study was run in recreational stimulant users.
Does Living Water Labs stock Tesofensine?
Not at present. Tesofensine is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
